Give Your Dog More Days of Play

Librela offers long-lasting pain relief with a once-a-month injection administered by your vet.1

Osteoarthritis (OA), or arthritis, is a painful chronic condition of the joints. Pain from OA can severely affect the health and well-being of your dog.2 Although we can’t cure OA, we can control the pain it causes, which can help your dog be more active and improve their overall quality of life.3-6

Ask your vet about the newest osteoarthritis injection for dogs.

Are you missing the signs of your dog’s OA pain? Complete our quick checklist.
illustration of dog with checkmark
Librela product image

One Monthly Injection of Librela Can Reduce Your Dog's OA Pain

By reducing OA pain and helping to restore mobility, your dog can feel better and you can get back to the activities you 
both love.1-6

Why Librela for Dogs?

  • By decreasing OA pain, Librela can increase your dog's activity and improve their quality of life.1, 3, 4
  • Effectively controls Canine OA pain with a once-a-month injection given by a veterinary professional.1
  • Available in Europe since 2021, with over 6.8 million doses distributed.9
Illustration of pack of dogs

What Is Dog OA Pain?

OA is a chronic and painful condition that causes your dog to hurt all the time if left untreated.2

  • OA is a type of arthritis that happens when protective tissue in the joints is worn down, causing bones to rub against one another.
  • Dogs of all ages, sizes, and breeds can have OA pain—it’s not just a condition seen in older dogs.10
  • OA decreases your dog’s willingness to play, affects their quality of life, and makes it hard for you to do the things you love together.

Vet-Approved Support

Librela FAQ

IMPORTANT SAFETY INFORMATION: See full Prescribing Information. For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis.

  1. Librela (bedinvetmab injection). Prescribing information. NADA 141-562. Zoetis Inc; March 2023.
  2. Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey M. Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017. Vet J. 2019;250:71-78. doi:10.1016/j. tvjl.2019.07.001.
  3. Brown DC, Boston RC, Coyne JC, Farrar JT. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. Am J Vet Res. 2007;68(6):631-637. doi:10.2460/ajvr.68.6.631.
  4. Brown DC, Boston RC, Coyne JC, Farrar JT. Ability of the Canine Brief Pain Inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. 2008;233(8):1278-1283. doi:10.2460/ javma.233.8.1278.
  5. Corral, Maria J., et al. "A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis." Veterinary anaesthesia and analgesia 48.6 (2021): 943-955.
  6. Michels GM et al. Vet Anaesth Analg. 2023;50(5):446-458. doi:10.1016/j.vaa.2023.06.003
  7. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493-507. doi:10.2165/11531280.
  8. Isola M et al. Vet Comp Orthop Traumatol. 2011;24(4):279-284. doi:10.3415/VCOT-10-04-0051.
  9. Data on file. Zoetis Inc. May 2023.
  10. Anderson KL et al. Front Vet Sci. 2020;7:200. doi:10.3389/fvets.2020.00220
  11. Wright A et al. J Small Anim Pract. 2022;63(8):609-618. doi:10.1111/jsap.13500